Germany-based Datwyler plans to build a more than $102 million drug delivery systems production plant in Middletown, Delaware.
According to company officials the plant “will be used to manufacture high-quality elastomer components for injectable drug delivery systems. The new, highly automated facility in the U.S. meets the most stringent quality standards."
Construction work likely to get under way before the end of 2016, with production is scheduled to start in the first half of 2018. Once it is fully up and running, Datwyler's new, highly automated plant is expected to provide jobs for around 120 employees.
“With its new production site in Delaware, the company will be able to significantly boost its position in the world's largest pharmaceutical market. The new plant is to be designed, built and run in accordance with Datwyler's latest "FirstLine" standards. This will make it possible to provide customers in the three key business regions of the U.S., Europe and Asia with locally produced first-line components in future,” company officials said.
The "FirstLine" standards comprise a manufacturing concept for high-quality elastomer components based on ultra-modern clean room technology, automated production cells, fully automated camera inspection and a unique washing process, company officials explained.This innovative approach to manufacturing exceeds the most stringent quality standards of the European and U.S. regulatory authorities and is certified to ISO 15378.
Datwyler, which made a concept plan presentation to town officials, will have to go through a preliminary and final plan approval process.